Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials

Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?

(2015) N. Vodovar et al.   EUROPEAN HEART JOURNAL

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

(2015) Adriaan A. Voors et al.   EUROPEAN JOURNAL OF HEART FAILURE

Neprilysin inhibitors preserve renal function in heart failure

(2015) Fiona Bodey et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension

(2014) Kazuomi Kario et al.   HYPERTENSION

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study

(2014) Bryan Williams et al.   BMJ Open

Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure

(2014) Orly Vardeny et al.   JACC-Heart Failure

Do angiotensin receptor blockers prevent Alzheimerʼs disease?

(2013) Ihab Hajjar et al.   CURRENT OPINION IN CARDIOLOGY

Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation

(2013) Kazuomi Kario   HYPERTENSION RESEARCH

Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial

(2013) Aneliya Parvanova et al.   Lancet Diabetes & Endocrinology

Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin–Angiotensin System Inhibitors

(2012) Harikrishna Makani et al.   AMERICAN JOURNAL OF CARDIOLOGY

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

(2012) Scott D Solomon et al.   LANCET

Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 Prevents Hypertensive Cardiac Remodeling in a Blood Pressure–Independent Manner

(2011) Philipp Kalk et al.   HYPERTENSION

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

(2011) Laxminarayan G Hegde et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Dual-Acting Angiotensin Receptor–Neprilysin Inhibition

(2010) Julian Segura et al.   CURRENT HYPERTENSION REPORTS

Flow-mediated constriction: further insight into a new measure of vascular function

(2010) T. Gori et al.   EUROPEAN HEART JOURNAL

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

(2007) R M Fryer et al.   BRITISH JOURNAL OF PHARMACOLOGY